[Healthcare Market sizing Question] Market size for cancer immunotherapy

healthcare pharma market size Market sizing
New answer on Jun 26, 2023
4 Answers
5.4 k Views
Anonymous A asked on Oct 14, 2019

How can I conduct market sizing for cancer immunotherapy? I think I have to add the segmentation of looking at cancer -> Cancer segments that can be treated with immunotherapy but I'm not sure if this goes first than the cancer diagnosed rates

Overview of answers

  • Upvotes
  • Date ascending
  • Date descending
Best answer
Content Creator
replied on Oct 14, 2019
Top rated McKinsey Case & PEI coach/Multiple real offers/McKinsey EM in New York /6 years McKinsey recruiting experience

This question can be very complicated without sufficient context setting

Immunotherapy is not indicated for all types of cancers and for the ones it is indicated for you typically need to test for biomarkers present to see if a patient is eligible. The % of population that has the biomarker differs for each type of cancer and each drug

In addition, current treatment protocol differs by segment - for example it is not always recommended as a first line treatment for all cancers, and often comes as 2nd line

One way to estimate the market size here is to

  • See which cancers can currently be treated with immunotherapy
  • Estimate incidence rates for these cancers by stage
  • Estimate the % of instances that can be treated with immuno therapy
    • This varies by cancer
    • Varies by stage of diagnosis
    • And requires the presence of a biomarker
  • The above is your addressable market for immunotherapy
  • The revenue model here is very tricky - each country has its own prices, in the US especially it depends on the contracts you have with the different payors, and treatment can easily go into hundreds of thousands of dollars per patient per year.
Was this answer helpful?
Marcus replied on Jun 05, 2023

What promising cancer therapies, such as immunotherapy or genetic approaches, offer new opportunities in the fight against cancer cells, and what clinical studies are exploring these areas to develop new drugs and therapeutic strategies?

Was this answer helpful?
Anonymous B replied on Oct 14, 2019

What I would do to approach this problem:

1. Start from population, estimate the amount of population with cancer. I would segment by age because I believe that cancer is much more prevalent in mature ages

2. I probably would've missed the diagnosed rate actually.

3. I would calculate % of people treated by immunotherapy, segmenting by income level since people with lower income will less likely be treated

4. Estimate amount of therapy one person require, probably by frequency (once a week?) and $/week (idk, 1k$?)

5. Calculate the final results

Let me know your thoughts

Was this answer helpful?
Vernan replied on Jun 26, 2023

Fenbendazole may sensitize tumors to radiation therapy https://www.fenbendazole.org/2019/12/19/panacur-c-dog-dewormer-for-cancer/ .A canine dewormer can be a significant option before and during radiation therapy. It sensitizes cancer cells to treatment in a manner similar to taxane chemotherapeutic agents. I also want to note that this is one of the best drugs at the moment.

Was this answer helpful?
Udayan gave the best answer


Content Creator
Top rated McKinsey Case & PEI coach/Multiple real offers/McKinsey EM in New York /6 years McKinsey recruiting experience
Q&A Upvotes
91 Reviews
How likely are you to recommend us to a friend or fellow student?
0 = Not likely
10 = Very likely